San Diego-centered Viking Therapeutics marked alone as a significant competitor during the weight loss drug market in February just after revealing promising information from a mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection As well as in March